Baxter International Inc (NYSE:BAX) SVP Jacqueline Kunzler sold 593 shares of Baxter International stock in a transaction that occurred on Wednesday, June 19th. The stock was sold at an average price of $80.46, for a total transaction of $47,712.78. Following the transaction, the senior vice president now owns 9,023 shares in the company, valued at $725,990.58. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of BAX stock traded down $0.88 on Friday, hitting $81.65. The company’s stock had a trading volume of 1,147,507 shares, compared to its average volume of 2,146,971. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.83 and a quick ratio of 1.30. Baxter International Inc has a fifty-two week low of $61.05 and a fifty-two week high of $82.85. The firm’s fifty day moving average price is $78.99. The firm has a market cap of $42.10 billion, a PE ratio of 26.77, a price-to-earnings-growth ratio of 1.94 and a beta of 0.99.
Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.08. Baxter International had a net margin of 14.27% and a return on equity of 20.04%. The business had revenue of $2.63 billion during the quarter, compared to analyst estimates of $2.61 billion. During the same quarter in the previous year, the business earned $0.70 EPS. Baxter International’s quarterly revenue was down 1.7% compared to the same quarter last year. As a group, equities analysts predict that Baxter International Inc will post 3.32 EPS for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc raised its stake in shares of Baxter International by 1.3% in the third quarter. Vanguard Group Inc now owns 36,398,931 shares of the medical instruments supplier’s stock worth $2,805,993,000 after purchasing an additional 470,198 shares during the last quarter. Advisors Asset Management Inc. raised its stake in shares of Baxter International by 26.1% in the fourth quarter. Advisors Asset Management Inc. now owns 29,060 shares of the medical instruments supplier’s stock worth $1,913,000 after purchasing an additional 6,022 shares during the last quarter. WINTON GROUP Ltd raised its stake in shares of Baxter International by 219.8% in the fourth quarter. WINTON GROUP Ltd now owns 8,481 shares of the medical instruments supplier’s stock worth $558,000 after purchasing an additional 5,829 shares during the last quarter. Whittier Trust Co. raised its stake in shares of Baxter International by 5.7% in the fourth quarter. Whittier Trust Co. now owns 6,251 shares of the medical instruments supplier’s stock worth $411,000 after purchasing an additional 339 shares during the last quarter. Finally, Sullivan Bruyette Speros & Blaney LLC raised its stake in shares of Baxter International by 3.6% in the fourth quarter. Sullivan Bruyette Speros & Blaney LLC now owns 4,322 shares of the medical instruments supplier’s stock worth $284,000 after purchasing an additional 150 shares during the last quarter. 83.97% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have recently commented on BAX shares. Cowen set a $75.00 price target on shares of Baxter International and gave the company a “hold” rating in a report on Monday, April 22nd. KeyCorp started coverage on shares of Baxter International in a report on Tuesday, June 25th. They set a “sector weight” rating on the stock. Wells Fargo & Co upgraded shares of Centurylink from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $12.00 to $14.00 in a report on Wednesday, June 26th. Zacks Investment Research cut shares of Gold Resource from a “hold” rating to a “sell” rating in a report on Friday, June 21st. Finally, Barclays boosted their price target on shares of Zimmer Biomet from $113.00 to $117.00 and gave the company an “underweight” rating in a report on Monday, April 15th. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $79.20.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Further Reading: What is a Market Correction?
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.